Parkinson's disease (PD) is pathologically characterized by the presence of α-synuclein (α-syn)-positive intracytoplasmic inclusions named Lewy bodies in the dopaminergic neurons of the substantia nigra. A series of morbid consequences are caused by pathologically high amounts or mutant forms of α-syn, such as defects of membrane trafficking and lipid metabolism. In this review, we consider evidence that both point mutation and overexpression of α-syn result in aberrant degradation in neurons and microglia, and this is associated with the autophagy-lysosome pathway and endosomelysosome system, leading directly to pathological intracellular aggregation, abnormal externalization and re-internalization cycling (and, in turn, internalization and re-externalization), and exocytosis. Based on these pathological changes, an increasing number of researchers have focused on these new therapeutic targets, aiming at alleviating the pathological accumulation of α-syn and re-establishing normal degradation.
Introduction
Alpha-synuclein (α-syn) is a small cytoplasmic protein that has specific relevance to Parkinson's disease (PD). The α-syn gene comprises six exons, and at least three isoforms are produced by alternative splicing, with different expression patterns and levels [1, 2] . Under normal conditions, α-syn exists in a random coil form in the cytoplasm. Although predominantly a neuronal protein, it is also found in glial cells [3] . A portion of this protein has been identified in vesicles and can be secreted from cells into blood plasma and cerebrospinal fluid via exocytosis [4, 5] . Growing evidence shows that α-syn is involved in the functioning of the neuronal Golgi apparatus and vesicle trafficking, as well as regulating the distribution and fusion of synaptic vesicles [6] . Larsen et al. [7] reported increased synaptic vesicle pools in PC12 cells overexpressing α-syn, while α-syn knockout mice have reduced docked and reserve synaptic vesicle pools in hippocampal neurons [8] . All these findings reflect the important functions of α-syn in regulating vesicle traffic.
α-Syn exists as a mix of unstructured, α-helix, and β-sheet-rich conformations in equilibrium, and on the basis of spatial conformation, a study in 2008 suggested that mutations known to enhance aggregation strongly increase the population of the β form. Hence, this could be a conformation associated with pathogenic aggregation [9] . Three missense mutations, A53T, A30P and E46K, as well as As α-syn is a classical cytosolic protein, its pathogenic effects were assumed to be limited to the cytoplasm of single cells. However, recent studies of extracellular α-syn
showed that this protein also has extracellular pathogenic actions. Significantly, a link between the extracellular aggregation of α-syn and the activation of microglia leading
to dopaminergic neurotoxicity has been demonstrated in several recent studies in vivo [10, 11] . Intracellular and extracellular α-syn are necessarily connected; the disruption of intracellular α-syn degradation causes its extracellular secretion. Extracellular α-syn is again internalized by recipient cells [12] . This dynamic relationship will be further described in detail in our review.
Externalization and internalization of aggregated α-syn in microglia and neurons
Mutant, overexpressed or oxidatively damaged α-syn can form soluble oligomers or insoluble fibers such as Lewy bodies, which cannot be easily hydrolyzed by the ubiquitin proteasome system. In a study by Su et al.,
MN9D cells overexpressing Wt α-syn and/or GFP under the regulation of tetracycline were untreated or exposed to doxycycline (DOX), a tetracycline analog that induces α-syn and GFP expression, and only the conditioned medium from MN9D SYN DOX-treated cells contained α-syn [13] .
Immunofluorescence showed a significant difference between normal neurons and those overexpressing α-syn:
overexpression of α-syn resulted in extensive protein accumulation primarily in cytoplasmic granular structures as well as in punctate structures located along the neuronal processes. α-Syn aggregates in cells when present in abnormal and pathological forms. Furthermore, it can be externalized into the medium and impair the viability of adjacent cells [14] .
In a study by Lee et al., differentiated SH-SY5Y cells were treated with 0.2 μmol/L α-syn fibrils for up to 48 h, and they found intracellular accumulation of the internalized α-syn fibrils, which reached a peak at 24 h [12] .
Further, ELISA quantification showed that the level of α-syn oligomers is elevated in the body fluids (e.g., cerebrospinal fluid and blood) of PD patients [15] . This suggests other cells in the brain such as astroglia [11, 17] . Moreover, unlike the endocytotic internalization of α-syn fibrils and oligomers, monomeric α-syn enters the cell through membrane transport (a non-endocytotic mechanism), and its internalization is much faster than that of the aggregated form [12] . Consistently, after internalization, monomers exist in the cytoplasm rather than in vesicles [12] . Researchers also found that protein-folding stresses and inhibition of protein quality control increase vesicle translocation and aggregation, indicating that damaged and aggregated proteins are preferentially secreted by cells [12] . That is, α-syn, which has been identified in vesicles, could be transported into the extracellular space via an endoplasmic reticulum/ Golgi-independent exocytosis pathway. α-Syn can activate microglia uniquely, with subsequently increased secretion of inflammatory factors such as intracellular reactive oxygen species, tumor necrosis factor-α and prostaglandin E2 [13, 18] . At this time, microglia plays the role of scavenger, 
Impaired intracellular degradation of α-syn
α-Syn exists in three common forms: monomers, dimers and protofibrils [19] . It is known that α-syn has a tendency to self-assemble under certain circumstances and form dimers and higher-order oligomeric species. Protein misfolding leads to the formation of amyloid-like fibrils, which is the key to Lewy body generation.
For some reasons (e.g., point mutation or injury), α-syn accumulates abnormally rather than entering the normal degradation pathway, thus becoming a potential risk factor. The cytotoxicity of α-syn mostly lies in its soluble or insoluble aggregated oligomers and polymers. Missense mutation, overexpression, or gene damage of α-syn undoubtedly increases the probability of its aggregation. All of these conditions appear to contribute at least partially to familial and sporadic PD [17, 18] .
Abnormal intracellular α-syn aggregation increases
cell toxicity mainly in the following ways: (1) by activating microglia to release inflammatory cytokines; (2) by stalling vesicular fusion (in yeast this specifically causes massive accumulation of vesicles and toxicity associated with disruption of endosome-Golgi trafficking [20] ); (3) by interfering with exocytosis and synaptic vesicle recycling in mammalian neurons [21] ; and (4) by inducing neurotoxicity (it has been reported that α-syn aggregates transmit pathology via neuron-to-neuron interactions [14, 22] ). Therefore, removal of α-syn from the extracellular space and elimination of its aggregated forms have emerged as critical problems with direct implications for neuronal function and survival.
Defect of the autophagy-lysosome pathway
In cell biology, autophagy or autophagocytosis involves the degradation of a cell's components through the lysosomal machinery. In general, autophagy is divided into macroautophagy, microautophagy and chaperone-mediated autophagy (CMA). Macroautophagy is the major lysosomal pathway for the degradation of intracytoplasmic proteins. One of its features is the non-specific bulk degradation of cellular contents through both selective and nonselective mechanisms, rather than directly transporting vesicles to lysosomes. In contrast, CMA degrades only soluble proteins, albeit in a selective manner [23] .
In the following section, we mainly focus on macroautophagy, together with a description of α-syn degradation by CMA. [25, 26] . Accordingly, inhibition of mTOR signaling (e.g. with rapamycin) induces autophagy [27] .
mTOR mainly functions to act as the inhibitory signal that shuts off autophagy in the presence of growth factors and abundant nutrients [28] . Thus, accumulation of abberant asyn, which can not be successfully degraded by autophagy, further interferes with fusion of lysosomes and formation of autophagosomes [29, 30] . This is in accord with the theory of Crews and and co-workers. On the other hand, activating autophagy with rapamycin or viral-mediated delivery of
Atg7 reduces the accumulation of α-syn and ameliorates the associated neuritic alterations [31] . Similar conclusions were also drawn by Spencer's test [16] .
LC3-II is essential for the formation of autophagosomes ( Fig.1) and measures of its levels have been widely used to estimate their abundance. Data have shown that the macroautophagy marker LC3-II does not co-localize
with the large α-syn aggregates either in brain tissue or in cultured cells, suggesting that these aggregates could not be eliminated successfully [32] . LC3-II is decreased in cells overexpressing Wt α-syn, while the PD-associated α-syn mutants A53T and A30P show no such effect [19] . While mTOR participates in the early stage of macroautophagy, double-immunolabeling analysis showed that mTOR and LC3-II increase in cells with the accumulation of α-syn, and both co-localize with aggregated α-syn [31] . Mutant forms of α-syn found in familial PD patients have been [24] .
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shown to block autophagy. The impairing effect of A53T
and A30P mutant α-syn on autophagy may be ameliorated through degradation, albeit in a much lower efficient, of the mutants by CMA targeting [33] .
Upon completion of the double-membrane structure of the autophagosome, Atg4 removes LC3-II from the outer autophagosomal membrane in a process called deconjugation. But LC3-II remains associated with the inner membrane and thus becomes partially degraded after fusion with the lysosome [26] . Bafilomycin A1 blocks the degradation of LC3-II, and this allows the specific assessment of LC3-II formation rates. However, LC3-II levels still decrease in cells overexpressing α-syn in the presence of bafilomycin A1. Therefore, Winslow concluded that the decrease in LC3-II levels caused by α-syn is a result of impaired autophagosome synthesis rather than changes in the function of autolysosomes or lysosomes [19] . In vivo, the effect of the α-syn transgene on LC3-II levels is dose-dependent in the mouse brain [19] . However, the author could not attribute this to a reduction of autophagosome formation or an increase of delivery from antophagosome to lysosome [19] . Using an immunofluorescence method, Spencer et al. found that compared to the lentivirus (LV) control, abundant, enlarged LC3-GFP structures >1 µm in diameter occurred in serum-starved LV-α-syn neurons [16] . So we can conclude that overexpressing α-syn destroys or changes the normal pathway of autophagy, and these assays reveal a decrease in omegasome formation (the omegasome is a newly characterized structure thought to be the precursor of the forming autophagosome) [19] .
The lysosome: late in the autophagy process
Lysosomal dysfunction causes a dramatic increase in total α-syn release into the cellular medium, as revealed by
Western blot and immunofluorescence [34] . Immunofluorescent staining of α-syn in SH-SY5Y cells overexpressing Wt α-syn show peri-nuclear accumulation of α-syn [34] .
As noted above, secreted α-syn causes neuropathological changes and neuronal death. stated that over-expression of A53T α-syn in human SH-SY5Y cells is responsible for the decrease in total lysosomal protein degradation [30] . Also interesting is that overexpression of human A53T α-syn in rat primary neurons causes a significant reduction of CMA activity, followed by a compensatory increase in macroautophagy. Thus, the best guess is that there is some kind of contact between macroautophagy and CMA, which may be in a dynamic, complementary balance. Overexpression of Wt or A53T α-syn acts as an inducing factor that activates the scavenging capacity of these two kinds of autophagy, but this aberrant protein ultimately impairs the normal autophagylysosome pathway. lin-1 proteins [12] . These proteins are markers of endosomes and lysosomes, or are closely associated with the formation of endosomes. Dynamin is one of the GTPases which is essential for generating endocytic vesicles. Researchers found that the expression of dominant-negative dynamin-1 K44A, which is inactive as a GTPase, blocks endocytosis, resulting in the location of most of the α-syn fibrils on the cell surface, with little cytoplasmic staining [12] . Lee also demonstrated that degradation of α-syn through the lysosome pathway is the main mode. Although much remains to be uncovered in the defective degradation of α-syn via the endosome-lysosome pathway, blocking endocytosis or the formation of endocytic vesicles would lead to imperfect degradation of α-syn. Moreover, 25 μmol/L chloroquine which disturbs the membrane trafficking from endosomes to lysosomes [35] , dramatically increases the secretion of α-syn [14] . This is consistent with the theory noted above that the endocytic pathway may be involved in α-syn secretion.
Endosome-lysosome pathway
Having confirmed that recycling endosomes are involved in the trafficking of intracellular α-syn, Liu et al. [36] proposed another reason for the failure of α-syn elimination by lysosomes [36] . Rab11a, an important member of the Rab GTPase protein family that regulates the function of recycling endosomes, participates in endosome-mediated α-syn exocytosis. In brief, the internalized α-syn can be managed by exocytosis, in addition to the endosome-lysosomedependent degradation pathway. Further tests using confocal microscopy demonstrated that A53T mutant α-syn co-localizes with Rab11a. α-Syn becomes toxic in yeast upon its association with vesicles forming at the plasma membrane. Thereby, in theory, α-syn enters the vacuolar degradation pathway; however, since it is excluded from the vacuole, α-syn recycles from endosomes back to the plasma membrane [37] . We suppose that there may be some proteins that function to transport and sort specific proteins and guide them into the correct degradation pathway. But this continuous cycle might eventually lead to saturation and blockade of endocytosis and vesicular trafficking routes that merge with the endocytic protein-sorting machinery. Undoubtedly, the endosome-lysosome pathway would be disturbed.
Potential new therapeutic targets
One pathological feature of PD-insoluble aggregates composed largely of α-syn in certain populations of neurons and glia-has been attracting increasing concern from re- Spencer et al. [16] proposed that beclin 1 may be a novel therapeutic target for PD treatment, and neuropathological analysis and animal experiments demonstrated that beclin 1 injections ameliorate the synaptic and dendritic pathology in α-syn transgenic mice and reduce the accumulation of α-syn in the limbic system without any significant deleterious effects. This is accompanied by enhanced lysosomal activation and reduced changes in the autophagy pathway (e.g., abnormal aggregation and enlargement of autophagic vesicles marked with LC3-II GFP) [34] . These results imply that a therapeutic approach with rapamycin or beclin 1 might act to re-establish the physiological autophagy-lysosome pathway, thereby playing a positive role in regulating autophagy.
Gangliosides
Gangliosides are composed of a glycosphingolipid (ceramide and oligosaccharide) with one or more sialic acids (e.g. n-acetylneuraminic acid) linked to the sugar chain. Natural and semisynthetic gangliosides are considered to be possible therapeutic agents for neurodegenerative disorders [38] . In a study by Wei et al. [39] , cells overexpressing P123H β-syn were transfected with control vectors, Wt α-syn, or A53T α-syn. Treatment of these cells
, an inhibitor of glycosyl ceramide synthase, results in various pathological features, including compromised lysosomal activity, enhanced lysosomal membrane permeabilization, and increased cytotoxicity [39] .
Consistent with these findings, the expression levels of the lysosomal membrane proteins ATP13A2 and LAMP- 
Summary
Defective intracellular degradation of α-syn in PD results from a great many of impairments of the degradation progress. Cell-mediated removal of extracellular α-syn may play a crucial role in maintaining an aggregatefree microenvironment and could be a therapeutic target to delay or arrest the progression of neuronal damage.
In this review, we discussed the alterations after overexpressing α-syn or in A53T or A30P mutants. α-Syn specifically activates microglia, causing damage to neurons.
This protein may also be involved in the internalizationexocytosis-re-internalization cycle, and through this may enter receptive cells intermittently. This process is related to the endosome-lysosome pathway, yet some researchers hold the opinion that intracellularly accumulated proteins are degraded through the autophagic-lysosomal pathway while extracellular proteins pass through the endosomallysosomal pathway. Any defect of these two pathways will bring about abnormalities in α-syn degradation, further increasing the cytotoxicity.
In addition, as far as autophagy is concerned, different treatments, such as rapamycin, beclin1, and natural and semisynthetic gangliosides can alleviate the accumulation of α-syn, thus ameliorating the related neuropathology [34] .
Overexpressing Rab1a can rescue the decrease in autophagosomes resulting from overexpression of α-syn, while for exocytosis and endocytosis, hindering the interaction between Rab11 and HSP90, or using inhibitors of these two proteins can undoubtedly reduce the extracellular level of α-syn to a certain extent, according to the experiments of Liu et al. [36] . It is also possible that as yet unknown drugs or improvement of certain proteins that function to transport and sort specific proteins into the correct degradation pathway, could further reduce the pathological damage in PD.
